BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35019173)

  • 1. A comprehensive profiling of soluble immune checkpoints from the sera of patients with non-small cell lung cancer.
    Peng Y; Zhang C; Rui Z; Tang W; Xu Y; Tao X; Zhao Q; Tong X
    J Clin Lab Anal; 2022 Feb; 36(2):e24224. PubMed ID: 35019173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble Immune Checkpoint-Related Proteins in Blood Are Associated With Invasion and Progression in Non-Small Cell Lung Cancer.
    Wang Q; He Y; Li W; Xu X; Hu Q; Bian Z; Xu A; Tu H; Wu M; Wu X
    Front Immunol; 2022; 13():887916. PubMed ID: 35874720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
    Datar I; Sanmamed MF; Wang J; Henick BS; Choi J; Badri T; Dong W; Mani N; Toki M; Mejías LD; Lozano MD; Perez-Gracia JL; Velcheti V; Hellmann MD; Gainor JF; McEachern K; Jenkins D; Syrigos K; Politi K; Gettinger S; Rimm DL; Herbst RS; Melero I; Chen L; Schalper KA
    Clin Cancer Res; 2019 Aug; 25(15):4663-4673. PubMed ID: 31053602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma.
    Ueda K; Uemura K; Ito N; Sakai Y; Ohnishi S; Suekane H; Kurose H; Hiroshige T; Chikui K; Nishihara K; Nakiri M; Suekane S; Ogasawara S; Yano H; Igawa T
    Curr Oncol; 2024 Mar; 31(4):1701-1712. PubMed ID: 38668032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
    Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
    J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of immune checkpoint regulators and potential role of soluble TIM-3 and LAG-3 in male patients with alcohol-associated liver disease.
    Fadriquela A; Kim CS; Lee KJ; Kang SH; Lee JH
    Alcohol; 2022 Feb; 98():9-17. PubMed ID: 34695559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer.
    Gao J; Qiu X; Li X; Fan H; Zhang F; Lv T; Song Y
    Biochem Biophys Res Commun; 2018 Apr; 498(3):409-415. PubMed ID: 29452091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
    Front Immunol; 2020; 11():1173. PubMed ID: 32587591
    [No Abstract]   [Full Text] [Related]  

  • 9. Soluble immune checkpoints are elevated in patients with primary biliary cholangitis.
    Gao X; Wang X; Guan Y; Wang L; Gao Y; Niu J
    Eur J Med Res; 2023 Nov; 28(1):477. PubMed ID: 37915081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
    Yang Q; Chen M; Gu J; Niu K; Zhao X; Zheng L; Xu Z; Yu Y; Li F; Meng L; Chen Z; Zhuo W; Zhang L; Sun J
    Front Immunol; 2021; 12():665133. PubMed ID: 33936103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer.
    Yang X; Zhang Q; Zhang M; Su W; Wang Z; Li Y; Zhang J; Beer DG; Yang S; Chen G
    Int J Biol Sci; 2019; 15(8):1712-1722. PubMed ID: 31360113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
    Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
    Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.
    Akbar S; Raza A; Mohsin R; Kanbour A; Qadri S; Parray A; Zar Gul AR; Philip A; Vijayakumar S; Merhi M; Hydrose S; Inchakalody VP; Al-Abdulla R; Abualainin W; Sirriya SA; Al-Bozom I; Uddin S; Khan OM; Mohamed Ibrahim MI; Al Homsi U; Dermime S
    Front Immunol; 2022; 13():1097117. PubMed ID: 36741391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
    Pyo JY; Yoon T; Ahn SS; Song JJ; Park YB; Lee SW
    Sci Rep; 2022 Dec; 12(1):21319. PubMed ID: 36494415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
    Fan J; Yu H; Lv Y; Yin L
    Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
    Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
    J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Autoantibody Against Human DNA-Topoisomerase I Is a Novel Biomarker for Non-Small Cell Lung Cancer.
    Wu WB; Yie SM; Ye SR; Xie K; Zhang JB; Cao M; Chen J; He X; Ma XL; Zhang J
    Ann Thorac Surg; 2018 Jun; 105(6):1664-1670. PubMed ID: 29453962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
    Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
    J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
    Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.